- Prescribe by brand name. Only NACSYS brand is formulary
- NACSYS effervescent tablets contain 600mg acetylcysteine
- Discontinue use after 4-6 weeks if the patient fails to derive any benefit
Restrictions: Restricted to specialist initiation for use in cystic fibrosis patients who are not currently using dornase alfa due to lack of response, intolerance or ineligibility and have rapidly declining lung function and in whom other osmotic agents are considered unsuitable.
Restrictions: Restricted to specialist initiation.
Responsibility for initiation, review and any necessary monitoring rests with specialist service.
Discontinue use after 4 weeks if the patient fails to derive any benefit (see BNF). The dose of carbocisteine should be reduced to a maintenance dose of 1.5g daily in divided doses as the patient's condition improves. Typically, such a dose reduction would be done after one month of treatment